BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Herat LY, Ward NC, Magno AL, Rakoczy EP, Kiuchi MG, Schlaich MP, Matthews VB. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. World J Gastroenterol 2020; 26(23): 3225-3235 [PMID: 32684737 DOI: 10.3748/wjg.v26.i23.3225]
URL: https://www.wjgnet.com/1007-9327/full/v26/i23/3225.htm
Number Citing Articles
1
Jennifer R. Matthews, Lakshini Y. Herat, Aaron L. Magno, Shelley Gorman, Markus P. Schlaich, Vance B. Matthews. SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for BeigingBiomedicines 2020; 8(11): 514 doi: 10.3390/biomedicines8110514
2
Shyamal Raolji, James Lai, Arjun Watane, Courtney Frances Goodman, Benjamin Chipkin, Anat Galor. Microbes, Microbial Metabolism, and Mucosal Immunity2024; : 229 doi: 10.1016/B978-0-323-90144-4.00006-9
3
Aaron L. Magno, Lakshini Y. Herat, Márcio G. Kiuchi, Markus P. Schlaich, Natalie C. Ward, Vance B. Matthews. The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-αJournal of Clinical Medicine 2020; 9(9): 2764 doi: 10.3390/jcm9092764
4
Qiong Yang, Ling Deng, Changmei Feng, Jianghua Wen. Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic micePeerJ 2024; 12: e17055 doi: 10.7717/peerj.17055
5
Fengqin Yuan, Tianlong Zhang, Sixiang Jia, Jianqiang Zhao, Binbin Wan, Gang Liu. Fine mapping-based multi-omics analysis interprets the gut-lung axis function of SGLT2 inhibitorsFrontiers in Cellular and Infection Microbiology 2024; 14 doi: 10.3389/fcimb.2024.1447327
6
Yanxia Chen, Mian Wang. New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 DiabetesDrug Design, Development and Therapy 2021; : 4849 doi: 10.2147/DDDT.S334325
7
Rosana M. C. Bastos, Antônio Simplício-Filho, Christian Sávio-Silva, Luiz Felipe V. Oliveira, Giuliano N. F. Cruz, Eliza H. Sousa, Irene L. Noronha, Cristóvão L. P. Mangueira, Heloísa Quaglierini-Ribeiro, Gleice R. Josefi-Rocha, Érika B. Rangel. Fecal Microbiota Transplant in a Pre-Clinical Model of Type 2 Diabetes Mellitus, Obesity and Diabetic Kidney DiseaseInternational Journal of Molecular Sciences 2022; 23(7): 3842 doi: 10.3390/ijms23073842
8
Aqsa Ashfaq, Myriam Meineck, Andrea Pautz, Ebru Arioglu-Inan, Julia Weinmann-Menke, Martin C. Michel. A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathyPharmacology & Therapeutics 2023; 249: 108503 doi: 10.1016/j.pharmthera.2023.108503
9
Jennifer Matthews, Lakshini Herat, Markus P. Schlaich, Vance Matthews. The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes StatusInternational Journal of Molecular Sciences 2023; 24(18): 14243 doi: 10.3390/ijms241814243
10
Le Deng, Yang Yang, Gaosi Xu. Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiotaBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2022; 1867(12): 159234 doi: 10.1016/j.bbalip.2022.159234
11
Qing Fang, Na Liu, Binjie Zheng, Fei Guo, Xiangchang Zeng, Xinyi Huang, Dongsheng Ouyang. Roles of Gut Microbial Metabolites in Diabetic Kidney DiseaseFrontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.636175
12
Lakshini Yasaswi Herat, Jennifer Rose Matthews, Moira Hibbs, Elizabeth Piroska Rakoczy, Markus Peter Schlaich, Vance Bruce Matthews. SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetesiScience 2023; 26(8): 107260 doi: 10.1016/j.isci.2023.107260
13
Dalia H. El-Kashef, Haitham M. Sewilam. Empagliflozin mitigates methotrexate-induced hepatotoxicity: Targeting ASK-1/JNK/Caspase-3 pathwayInternational Immunopharmacology 2023; 114: 109494 doi: 10.1016/j.intimp.2022.109494
14
Michael Poledniczek, Christoph Neumayer, Christoph W. Kopp, Oliver Schlager, Thomas Gremmel, Alicja Jozkowicz, Michael E. Gschwandtner, Renate Koppensteiner, Patricia P. Wadowski. Micro- and Macrovascular Effects of Inflammation in Peripheral Artery Disease—Pathophysiology and Translational Therapeutic ApproachesBiomedicines 2023; 11(8): 2284 doi: 10.3390/biomedicines11082284
15
Omar Azzam, Vance B. Matthews, Markus P. Schlaich. Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous systemCurrent Opinion in Nephrology & Hypertension 2022; 31(2): 135 doi: 10.1097/MNH.0000000000000767
16
Qinglian Hua, Yaling Han, Haifeng Zhao, Haowen Zhang, Bei Yan, Shengjie Pei, Xin He, Yue Li, Xiangyuan Meng, Lei Chen, Feng Zhong, Duo Li. Punicalagin alleviates renal injury via the gut-kidney axis in high-fat diet-induced diabetic miceFood & Function 2022; 13(2): 867 doi: 10.1039/D1FO03343C
17
Rosana MC Bastos, Érika B Rangel. Gut microbiota-derived metabolites are novel targets for improving insulin resistanceWorld Journal of Diabetes 2022; 13(1): 65-69 doi: 10.4239/wjd.v13.i1.65
18
Jinghua Jiao, Honghua Yu, Litong Yao, Lihua Li, Xiaohong Yang, Lei Liu. Recent Insights into the Role of Gut Microbiota in Diabetic RetinopathyJournal of Inflammation Research 2021; : 6929 doi: 10.2147/JIR.S336148
19
Yue Cai, Yongbo Kang. Gut microbiota and metabolites in diabetic retinopathy: Insights into pathogenesis for novel therapeutic strategiesBiomedicine & Pharmacotherapy 2023; 164: 114994 doi: 10.1016/j.biopha.2023.114994